Manufacturer of Controlled Substances; Notice of Application, 20001-20002 [2010-8797]
Download as PDF
<![CDATA[
20001
Federal Register / Vol. 75, No. 73 / Friday, April 16, 2010 / Notices
Drug
Schedule
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Acetyldihydrocodeine (9051) .......................................................................................................................................................................
Dihydromorphine (9145) ..............................................................................................................................................................................
Heroin (9200) ...............................................................................................................................................................................................
Normorphine (9313) ....................................................................................................................................................................................
Pholcodine (9314) .......................................................................................................................................................................................
Tilidine (9750) ..............................................................................................................................................................................................
3–Methylfentanyl (9813) ..............................................................................................................................................................................
Amphetamine (1100) ...................................................................................................................................................................................
Methamphetamine (1105) ...........................................................................................................................................................................
Methylphenidate (1724) ...............................................................................................................................................................................
Amobarbital (2125) ......................................................................................................................................................................................
Pentobarbital (2270) ....................................................................................................................................................................................
Secobarbital (2315) .....................................................................................................................................................................................
Phencyclidine (7471) ...................................................................................................................................................................................
Phenylacetone (8501) .................................................................................................................................................................................
Cocaine (9041) ............................................................................................................................................................................................
Codeine (9050) ............................................................................................................................................................................................
Dihydrocodeine (9120) ................................................................................................................................................................................
Oxycodone (9143) .......................................................................................................................................................................................
Hydromorphone (9150) ...............................................................................................................................................................................
Benzoylecgonine (9180) ..............................................................................................................................................................................
Ethylmorphine (9190) ..................................................................................................................................................................................
Hydrocodone (9193) ....................................................................................................................................................................................
Levorphanol (9220) .....................................................................................................................................................................................
Meperidine (9230) .......................................................................................................................................................................................
Methadone (9250) .......................................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) (9273) ..............................................................................................................................
Morphine (9300) ..........................................................................................................................................................................................
Thebaine (9333) ..........................................................................................................................................................................................
Oxymorphone (9652) ...................................................................................................................................................................................
Alfentanil (9737) ..........................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Fentanyl (9801) ...........................................................................................................................................................................................
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration, and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 17, 2010.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
VerDate Nov<24>2008
15:07 Apr 15, 2010
Jkt 220001
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: March 29, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–8792 Filed 4–15–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on February 23, 2010,
Siemens Healthcare Diagnostics Inc.,
Attn: RA, 100 GBC Drive, Mail Stop 514,
Newark, Delaware 19702, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Drug
Tetrahydrocannabinols (7370) .....
Ecgonine (9180) ...........................
Morphine (9300) ...........................
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Schedule
I
II
II
The company utilizes the listed
controlled substances in bulk to
manufacture in-vitro diagnostic test kits.
The company distributes the test kits for
sale to its customers. The process used
in manufacturing the test kits
irreversibly alters the controlled
substances involved in such a manner
that they are no longer classified as
controlled substances as defined under
the Controlled Substances Act.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 15, 2010.
E:\FR\FM\16APN1.SGM
16APN1
20002
Federal Register / Vol. 75, No. 73 / Friday, April 16, 2010 / Notices
Dated: March 29, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated October 16, 2009, and
published in the Federal Register on
October 28, 2009, (74 FR 55587), Varian
Inc., Lake Forest, 25200 Commercentre
Drive, Lake Forest, California 92630,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Phencyclidine (7471) ....................
1-Piperidinocyclohexanecarbonitrile (8603).
Benzoylecgonine (9180) ...............
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances for use in diagnostic
products.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Varian Inc., to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Varian
Inc., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: March 29, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Antitrust Division
Importer of Controlled Substances;
Notice of Registration
[FR Doc. 2010–8797 Filed 4–15–10; 8:45 am]
DEPARTMENT OF JUSTICE
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993 Joint Venture Under Tip
Award Number: 7ONANB1OHOO1
By Notice dated November 23, 2009,
and published in the Federal Register
on December 2, 2009 (74 FR 63156),
Mylan Pharmaceuticals Inc., 781
Chestnut Ridge Road, Morgantown,
West Virginia 26505, made application
by letter to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
Oxycodone (9143) ........................
Hydromorphone (9150) ................
The company plans to import the
listed controlled substances in finished
dosage form (FDF) for analytical testing
and distribution for clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Mylan Pharmaceuticals Inc. to import
the basic classes of controlled
substances is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Mylan Pharmaceuticals Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: March 29, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–8794 Filed 4–15–10; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2010–8796 Filed 4–15–10; 8:45 am]
BILLING CODE 4410–09–P
VerDate Nov<24>2008
16:37 Apr 15, 2010
Jkt 220001
II
II
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
Notice is hereby given that, on
February 3, 2010, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’), the
Joint Venture under TIP Award Number:
7ONANB1OHOO1 (‘‘Brewer-Swent’’) has
filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing (1) the identities
of the parties to the venture and (2) the
nature and objectives of the venture.
The notifications were filed for the
purpose of invoking the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances.
Pursuant to section 6(b) of the Act, the
identities of the parties to the venture
are: Brewer Science, Inc., Rolla, MO;
and SouthWest Nano Technologies,
Norman, OK. The general area of
Brewer-Swent’s planned activity is to
demonstrate the production of low-cost,
high-quality metallic and
semiconducting single wall carbon
nanotube inks.
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. 2010–8573 Filed 4–15–10; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—OpenSAF Foundation
Notice is hereby given that, on March
11, 2010, pursuant to section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), OpenSAF Foundation
has filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Aricent Technologies
(holding) Ltd., Gurgaon, Haryana,
INDIA; GoAhead Software, Belleirue,
WA; and Oracle Corporation, Santa
E:\FR\FM\16APN1.SGM
16APN1
]]>Agencies
[Federal Register Volume 75, Number 73 (Friday, April 16, 2010)]
[Notices]
[Pages 20001-20002]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-8797]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on February 23, 2010, Siemens
Healthcare Diagnostics Inc., Attn: RA, 100 GBC Drive, Mail Stop 514,
Newark, Delaware 19702, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in
schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)............... I
Ecgonine (9180)............................ II
Morphine (9300)............................ II
------------------------------------------------------------------------
The company utilizes the listed controlled substances in bulk to
manufacture in-vitro diagnostic test kits. The company distributes the
test kits for sale to its customers. The process used in manufacturing
the test kits irreversibly alters the controlled substances involved in
such a manner that they are no longer classified as controlled
substances as defined under the Controlled Substances Act.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than June 15, 2010.
[[Page 20002]]
Dated: March 29, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-8797 Filed 4-15-10; 8:45 am]
BILLING CODE 4410-09-P
